‘Not Just Growth In AG Xyrem’ Hikma Underlines Following Strong 2023

Lessening Of US Pricing Pressures Also Helps Put Hikma Back On An Even Keel

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Hikma welcomed a strong and profitable 2023, driven by the nourishing effects of its authorized generic Xyrem product, which will fall back this year as the rate of royalties owed to the brand’s innovator climbs. But the company is optimistic it can continue growth in 2024, including through its $1.2bn Injectables division, which rushed in to fill supply gaps last year.

SC1807_Market Growth_572387551_1200.jpg

Hikma’s management was keen to emphasize the growth potential for its other slate of portfolios and businesses after the company’s US authorized generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution soared above expectations in 2023, driving the London-listed firm’s annual Generics sales up by two-fifths to $937m, on the back of an admittedly “tough” 2022.

Moving into 2024, Hikma will step up significantly the royalties it will pay Jazz for the product. The firm debuted...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By Nabil and Olga Zviezdicheva

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

ADHD

This is regarding ADHD.

GB-Business-Free-DisclosureDevelopments-The Secret to Walking More: It’s Not Counting Steps

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.